CGEM Cullinan Oncology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CGEM

Price (delayed)

$25.3

Market cap

$1.09B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.69

Enterprise value

$994.72M

Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build ...

Highlights
The debt has declined by 28% year-on-year and by 10% since the previous quarter
CGEM's quick ratio is down by 20% YoY and by 17% from the previous quarter
Cullinan Oncology's equity has decreased by 15% YoY and by 3.2% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cullinanoncology.com

Key stats

What are the main financial stats of CGEM
Market
Shares outstanding
43.07M
Market cap
$1.09B
Enterprise value
$994.72M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.39
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$167.28M
EBITDA
-$166.97M
Free cash flow
-$134.48M
Per share
EPS
-$3.69
Free cash flow per share
-$3.24
Book value per share
$10.61
Revenue per share
$0
TBVPS
$11.65
Balance sheet
Total assets
$484.18M
Total liabilities
$30.29M
Debt
$3.59M
Equity
$453.7M
Working capital
$452.05M
Liquidity
Debt to equity
0.01
Current ratio
17.07
Quick ratio
16.6
Net debt/EBITDA
0.57
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-30.4%
Return on equity
-32.1%
Return on invested capital
-44.4%
Return on capital employed
-36.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CGEM stock price

How has the Cullinan Oncology stock price performed over time
Intraday
31.43%
1 week
61.56%
1 month
50.77%
1 year
152.5%
YTD
148.28%
QTD
48.47%

Financial performance

How have Cullinan Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$191.09M
Net income
-$153.16M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 7% from the previous quarter

Growth

What is Cullinan Oncology's growth rate over time

Valuation

What is Cullinan Oncology stock price valuation
P/E
N/A
P/B
2.39
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The price to book (P/B) is 166% higher than the last 4 quarters average of 0.9
Cullinan Oncology's equity has decreased by 15% YoY and by 3.2% from the previous quarter

Efficiency

How efficient is Cullinan Oncology business performance
CGEM's return on invested capital has dropped by 197% year-on-year and by 8% since the previous quarter
The company's return on assets fell by 2% QoQ
Cullinan Oncology's return on equity has decreased by 2.2% QoQ

Dividends

What is CGEM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CGEM.

Financial health

How did Cullinan Oncology financials performed over time
CGEM's quick ratio is down by 20% YoY and by 17% from the previous quarter
The current ratio has declined by 19% year-on-year and by 16% since the previous quarter
The debt is 99% smaller than the equity
The debt has declined by 28% year-on-year and by 10% since the previous quarter
Cullinan Oncology's equity has decreased by 15% YoY and by 3.2% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.